Tresiba, in combination with insulin aspart, effectively improved long-term glycemic control….

IL-13, a cytokine produced by activated Th-2 lymphocytes, is involved in several stages of beta cell maturation and differentiation….

What kind of content is viewed can affect the amount and type of food eaten….

Researchers believe that microbes may influence our decisions by releasing signaling molecules into our gut…. 

DMR procedure could improve glycemic control in type 2 diabetes patients….

For the past 18 months we have been providing you with a monthly newsletter with special features focused on GLP-1 analogs. These newsletters have provided information beginning with the first discovery of GLP-1 and GIP in the body and how they worked to control glucose levels, and have included practice …

There has been a lot going on with drugs in the GLP-1 agonist class over the past few months. First we added Tanzeum (albiglutide) as a once-a-week drug. Then the new Bydureon pen was introduced, and finally, Lilly got their once-weekly auto-injector pen product Trulicity (dulaglutide) approved by the FDA. …

In 1969, the group Santana first recorded the song "Evil Ways" with these lines, "You’ve got to change your evil ways, baby … You’ve got to change, baby, And every word that I say is true…." It seems that when it comes to the treatment of type 2 diabetes, we actually …

FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes Once-weekly dulaglutide was approved based on six clinical trials involving a total of 3,342 patients who received the drug. It was studied as a stand-alone therapy and in combination with metformin, sulfonylurea, thiazolidinedione, and prandial insulin. 

This was a busy week in the GLP-1 arena. An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk’s latest weight-loss drug, Saxenda. This medication, which is liraglutide 3 mg, was recommended as an adjunct to diet and exercise in adults with a BMI of 30 or more, …